

◀ EDUCATIONAL SERIES ▶

Organised by:



# ONCOLOGY MASTER CLASS

Save The Date

Friday, Saturday  
21<sup>st</sup> & 22<sup>nd</sup> January 2021  
05.30 pm - 08.00 pm.

## Lung Cancer

Organizing Chairman



**Dr. Ashok Kumar Vaid**

Chairman  
Medical Oncology and Hematology  
Medanta, The Medicity  
Gurugram

**Register Now**

Conference Managed by:



Leader in Physical, Hybrid & Virtual Conferences

# Agenda

Day 1 - 21<sup>st</sup> January 2022

- Low-Dose CT Screening for Lung Cancer in High-Risk Population: Is it Really Beneficial?
- Accurately identifying molecular alterations and Individualizing care for patients with NSCLC
- Liquid Biopsy: should we only reserve when tissue is an issue (or there are other applications in Lung Cancer)
- Oncomine: Oncology NGS testing solutions
- Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement
- Current and Future Directions in the Management of ROS1-Positive NSCLC
- Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC
- Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC
- Leveraging Biomarker Testing for HER2, HER3, and TROP2 in Metastatic NSCLC to Determine the Right Treatment for the Right Patient
- Managing toxicities of IOs and TKIs

# Agenda

Day 2 - 22<sup>nd</sup> January 2022

- Overview of Immunotherapy in Nonmetastatic NSCLC
- Current immunotherapy landscape in advanced NSCLC
- New directions: neoadjuvant and adjuvant immunotherapy in early-stage NSCLC
- Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC
- Current immunotherapy landscape in advanced NSCLC
- Current and Future Directions in the Management of ROS1-Positive NSCLC
- Immune resistance and sequencing of therapy
- Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC
- Emerging biomarkers of response to ICI therapy in NSCLC
- Immunotherapy in Advanced or Metastatic NSCLC: Special Populations
- Response to ICI-based therapy in patients with cachexia
- ICI-based therapy in patients with autoimmune disease and those who have undergone transplantation